Product Specifications:
Item# 1021: Recombinant HIV-1 MN Envelope Glycoprotein gp120 (Baculovirus).
Concentration: See vial
Mass/vial: 100ug
Diluent: PBS
Purity: >95%
Stabilizer: None
Preservative: None
Storage: -75°C
Physical State: Frozen
Liquid Stability: At least 24 months at -75°C.
Applications: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies.
Description: Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp120 glycoprotein produced in the Baculovirus Expression System.
Purification: This protein is purified by immuno-affinity chromatography to >95% purity as determined by SDS-PAGE, reduced.
Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western ELISA.
Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells.
Application and Instructions for use:
Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 10-100ng of immobilized protein under standard ELISA conditions.
Related Clinical Trials
| Official Title: | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults |
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Intervention:
Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
Group 1: low-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 2: high-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 3: AIDSVAX B/E (injection contains each of the two vaccine components, HIV-1 MN rgp120 and A244 rgp120/HIV-1) plus QS-21 plus alum (13 volunteers).
Group 4: high-dose MN rgp120/HIV-1 plus QS-21 plus alum (13 volunteers). Group 5: placebo plus QS-21 (8 volunteers). Volunteers will be closely monitored after each immunization and followed for a minimum of 12 months after the initial immunization.
immunodx重组抗原重组抗原是从实验室而不是从其生物学来源人工制造的抗原。就像天然抗原一样，它们能够使免疫系统发挥作用，从而使人体免受伤害。 并非市场上所有的重组抗原都是相同的。来自我们的 ImmunoDX具有极高的质量，并且与天然同类产品高度相似。 为了生产理想用于各种研究和诊断目的的重组抗原，我们使用了一些最具创新性和可靠性的蛋白质工程方法。由于一切都在我们的工厂中进行，因此我们保证了重组抗原纯度，特异性和生物活性的高水平标准。 我们的重组抗原以相同的方式非常接近天然抗原。但是，它们的生产不受诸如高需求和高税率等约束因素的影响。ImmunoDX可以以少量成本提供大量一流的重组抗原。 ImmunoDX的重组抗原非常适合 各种各样的应用，包括用于产生商业用途抗体的免疫程序。 多年来，ImmunoDX一直专门从事与关节炎，癌症，结核病，艾滋病等相关的研究和诊断的特殊生物学产品的生产。我们还提供许多其他相关的产品和服务。
